ADAM10 and early-onset autosomal dominant Alzheimer disease: From other reports it is evident that manipulation of ADAM10 in embryonic or early ontogenic stages could have severe side effects but therapeutic approaches concerning Alzheimer's disease always will focus on adult patients.